Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Recher

Showing results (41-50 of 136) with videos related to

Pageof 14
Sort By:
Cancer Research|May 6, 2004
Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosisChristian Recher, Loïc Ysebaert, Odile Beyne-Rauzy, et al.
Kidney International Reports|March 18, 2021
Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL-Negative Myeloproliferative NeoplasmsJulie Belliere, Magali Colombat, Clément Kounde, et al.
Pharmaceutics|April 23, 2022
Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 TrialGuillaume Drevin, Marie Briet, Caroline Bazzoli, et al.
Future Oncology (London, England)|November 19, 2025
Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed <i>IDH1</i> mutant AMLSamantha Nier, Jana Pelouchova, Ralph Hills, et al.
Future Oncology (London, England)|November 16, 2025
ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed <i>IDH1</i> mutant acute myeloid leukemiaParesh Vyas, Sam Salek, Susana Vives, et al.
Genes, Chromosomes & Cancer|December 13, 2005
EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangementsBruce Poppe, Nicole Dastugue, Jo Vandesompele, et al.
International Journal of Clinical Pharmacy|July 12, 2011
Induction-related cost of patients with acute myeloid leukaemia in FranceVirginie Nerich, Bruno Lioure, Maryline Rave, et al.
Hematological Oncology|October 15, 2014
Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosisStanislas Faguer, François Vergez, Michael Peres, et al.
Haematologica|May 12, 2018
<i>NPM1</i> mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agentsPedro Henrique Prata, Cécile Bally, Thomas Prebet, et al.
Leukemia & Lymphoma|November 12, 2020
Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patientsChloé Medrano, Lucie Oberic, Florent Puisset, et al.
Pageof 14

Showing results (41-50 of 136) with videos related to

Sort By:
Pageof 14
Cancer Research|May 6, 2004
Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosisChristian Recher, Loïc Ysebaert, Odile Beyne-Rauzy, et al.
Kidney International Reports|March 18, 2021
Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL-Negative Myeloproliferative NeoplasmsJulie Belliere, Magali Colombat, Clément Kounde, et al.
Pharmaceutics|April 23, 2022
Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 TrialGuillaume Drevin, Marie Briet, Caroline Bazzoli, et al.
Future Oncology (London, England)|November 19, 2025
Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed <i>IDH1</i> mutant AMLSamantha Nier, Jana Pelouchova, Ralph Hills, et al.
Future Oncology (London, England)|November 16, 2025
ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed <i>IDH1</i> mutant acute myeloid leukemiaParesh Vyas, Sam Salek, Susana Vives, et al.
Genes, Chromosomes & Cancer|December 13, 2005
EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangementsBruce Poppe, Nicole Dastugue, Jo Vandesompele, et al.
International Journal of Clinical Pharmacy|July 12, 2011
Induction-related cost of patients with acute myeloid leukaemia in FranceVirginie Nerich, Bruno Lioure, Maryline Rave, et al.
Hematological Oncology|October 15, 2014
Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosisStanislas Faguer, François Vergez, Michael Peres, et al.
Haematologica|May 12, 2018
<i>NPM1</i> mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agentsPedro Henrique Prata, Cécile Bally, Thomas Prebet, et al.
Leukemia & Lymphoma|November 12, 2020
Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patientsChloé Medrano, Lucie Oberic, Florent Puisset, et al.
Pageof 14